Averoa — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Averoa is a private, Paris-based biotech focused on the high-need nephrology sector, leveraging decades of industry experience from its founding team. The company is in a pre-revenue, early-stage development phase, building a pipeline to treat chronic kidney disease (CKD) and rare renal tubulopathies. With a leadership team that includes veterans from Advicenne and major pharma, Averoa combines deep clinical development expertise with a strategic regulatory vision to advance its programs.

NephrologyMetabolic Diseases

Technology Platform

Focus on small molecule therapeutics; emphasis on clinical development efficiency and regulatory strategy. Interest in complementary biomarker/diagnostic tools.

Opportunities

The large and growing prevalence of Chronic Kidney Disease (CKD), driven by aging populations and comorbidities like diabetes, presents a major addressable market.

Additionally, targeting rare renal tubulopathies offers opportunities for orphan drug designations, which provide regulatory incentives, market exclusivity, and potential for premium pricing.

Risk Factors

The company is at a very early, pre-clinical stage with an undisclosed pipeline, carrying high technical risk of failure.

As a private, pre-revenue entity, it faces significant funding risk and dependency on raising capital to sustain operations and advance its programs.

Competitive Landscape

The nephrology therapeutic space is competitive, with numerous large pharmaceutical companies and biotechs developing treatments for CKD and related complications. Averoa will need to differentiate through novel mechanisms of action, a focus on rare diseases, or its integrated approach combining therapeutics with diagnostic tools.

More companies in Small Molecule Drugs →More companies in France →